





















As a diversity of organism(s) undergo chronological 
aging, many genetic, phenotypic and metabolic defects 
accumulate, including the onset of senescence in a 
variety of cell types [1]. This overall view is consistent 
with the “accumulated damage” hypothesis of aging [2, 
3].  
 
Senescence is a clear hallmark of normal chronological 
aging. Senescence involves potentially  irreversible  cell  
 
cycle arrest, via the induction of CDK-inhibitors, such 
as p16-INK4A, p19-ARF, p21-WAF and p27-KIP1, as 
well as the onset of the SASP (senescence-associated 
secretory phenotype) [4], and the induction of key 
lysosomal enzymes (e.g., Beta-Galactosidase) and 
Lipofuscin, an established aging-pigment [5].  
Interestingly, SASP results in the secretion of a wide 
array of inflammatory cytokines, such as IL-1-beta and 
IL-6, allowing senescent cells to “contagiously” spread 
the senescence phenotype from one cell type to another, 
systemically throughout the body, via chronic 
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human  fibroblast cell  lines  (MRC‐5 and/or BJ) as model systems  to  induce senescence, via chronic  treatment
with a DNA‐damaging agent, namely BrdU  (at a concentration of 100 μM  for 8 days). Cell viability was  then
monitored by using the SRB assay, to measure protein content.  As a consequence of this streamlined screening
strategy,  we  identified  Azithromycin  and  Roxithromycin  as  two  novel  clinically‐approved  senolytic  drugs.
However,  Erythromycin  –  the  very  closely‐related  parent  compound  –  did  not  show  any  senolytic  activity,
highlighting  the  dramatic  specificity  of  these  interactions.  Interestingly,  we  also  show  that  Azithromycin
treatment of human fibroblasts was indeed sufficient to strongly induce both aerobic glycolysis and autophagy.
However,  the  effects  of  Azithromycin  on  mitochondrial  oxygen  consumption  rates  (OCR)  were  bi‐phasic,
showing inhibitory activity at 50 μM and stimulatory activity at 100 μM. These autophagic/metabolic changes
induced by Azithromycin could mechanistically explain  its senolytic activity.   We also  independently validated
our  findings  using  the  xCELLigence  real‐time  assay  system, which measures  electrical  impedance. Using  this
approach, we  see  that  Azithromycin  preferentially  targets  senescent  cells,  removing  approximately  97%  of
them with great efficiency. This represents a near 25‐fold reduction in senescent cells. Finally, we also discuss
our current results in the context of previous clinical findings that specifically document the anti‐inflammatory
activity of Azithromycin  in patients with  cystic  fibrosis – a  genetic  lung disorder  that  results  in protein mis‐
folding mutations that cause protein aggregation.  
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inflammation. Such chronic inflammation can also 
promote the onset of cancer, as well as drive tumor 
recurrence and metastasis [6, 7].  
 
Using the promoter of p16-IN4KA as a transgenic probe 
to detect and mark senescent cells, several research 
groups have now created murine models of aging in 
which senescent cells can be genetically eliminated in a 
real-time temporal fashion [8, 9].  Although this cannot 
be used as an anti-aging therapy, it can give us an 
indication whether the removal of senescent cells can 
potentially have therapeutic benefits to the organism. 
Results to date show great promise, indicating that the 
genetic removal of senescent cells can indeed prolong 
healthspan and lifespan [10, 11]. 
 
As a consequence of this exciting genetic data, a large 
number of pharmaceutical companies are now actively 
engaged in the discovery of “senolytic” drugs that can 
target senescent cells. However, we believe that many 
FDA-approved drugs may also possess senolytic 
activity and this would dramatically accelerate the 
clinical use of these senolytic drugs in any anti-aging 
drug trials.  
 
Here, we have used controlled DNA-damage as a tool to 
induce senescence in human fibroblasts, which then can 
be employed as an efficient platform for drug screening. 
More specifically, we employed BrdU-treatment, which 
has a long history of being used as a DNA-damaging 
agent, to reproducibly induce senescence in cultured 
cells, with high efficiency [12-17].  
 
Using this approach, we now report the identification of 
two macrolide antibiotics of the Erythromycin family, 





















clinically-approved senolytic drugs. In direct support of 
the high specificity of these complex interactions, the 
parent macrolide compound – Erythromycin itself – has 




Detection and characterization of “senolytic” 
activity during the screening of clinically-approved 
therapeutics 
 
Here, we used a simplified screening assay to identify 
and repurpose clinically-approved therapeutics with 
“senolytic” activity for the treatment of aging and 
















































Figure  1.  Targeting  senescent  cells  with  clinically‐
approved drugs. Here, we propose  to use clinically‐approved 
drugs,  including  antibiotics,  to  target  and  eliminate  senescent 
cells, with the goal of increasing healthspan and lifespan.  
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More specifically, we employed two independent 
normal, non-immortalized, human fibroblast cell lines, 
namely i) MCR-5 for screening and ii) BJ for validation 
(Figure 2). Mechanistically, the responses of “normal” 
fibroblasts and “senescent” fibroblasts were directly 
compared, side-by-side. Drugs that preferentially killed 
senescent fibroblasts, but not normal fibroblasts, were 
considered as a positive hit. Using this approach, we 
















































mycin and Roxithromycin that preferentially targeted 
senescent fibroblasts (Table 1). However, Erythromycin 
itself did not show any senolytic activity.  
 
Figure 3 shows a comparison of the precise chemical 
structures of the Erythromycin family members we 
tested. Note that the compounds are nearly identical, 
suggesting highly specific interactions must underpin the 
















































This  table briefly  summarizes  the biological effects of  three antibiotics, namely Erythromycin,



























































































































DNA‐synthesis  and  induces  Beta‐Galactosidase.  Two‐day
treatment with BrdU significantly reduced DNA synthesis in MRC‐5
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Furthermore, we validated previous findings that BrdU-
induced DNA-damage is indeed sufficient to induce 
cellular senescence.  Figure 4 shows that MRC-5 
fibroblasts treated with BrdU underwent cell cycle 
arrest, as evidenced by i) a ~70% reduction in the 
number of cells in S-phase and ii) the induction of Beta-
Galactosidase activity. 
 
Figures 5 directly shows that Azithromycin, at 100 μM, 
had no effect on the viability of normal MRC-5 lung 
fibroblasts, but selectively killed only senescent MCR-5 
fibroblasts. In comparison, Roxithromycin, at the same 
concentration, more effectively killed senescent MCR-5 
fibroblasts (~70%), but also had a small effect on the 
viability of normal MRC-5 fibroblasts (Figure 6). 
Neither drug showed any significant effects on viability 
at 50 μM, indicating that the effects we observed were 
concentration-dependent.  As such, Azithromycin 
toxicity showed the highest specificity for selectively 
targeting the senescent cell phenotype.  
 
Phenotypic and metabolic effects of Azithromycin in 
MRC-5 human fibroblasts 
 
To better mechanistically understand the phenotypic 
and metabolic effects of Azithromycin, we employed 






























Figure 7 shows that Azithromycin is an inducer of the 
autophagic phenotype. Autophagy was quantitatively 
measured by detection of autophagic LC3 proteins, 
using the Muse Autophagy LC3-antibody based kit. 
Note that Azithromycin treatment resulted in a > 3-fold 
elevation in autophagy in MRC-5 cells. 
 
We next measured the effects of Azithromycin on i) 
aerobic glycolysis and ii) mitochondrial metabolism, 
using the Seahorse XFe96 metabolic flux analyzer. 
Figure 8 shows that even low concentrations of 
Azithromycin (25 μM) effectively induced glycolytic 
flux in MRC-5 fibroblasts, in the presence of oxygen.  
 
Moreover, the effects of Azithromycin on mitochondrial 
oxygen consumption rate (OCR) are highlighted in 
Figure 9A,B. Note that the mitochondrial effects of 
Azithromycin were concentration-dependent and bi-
phasic. At 25 μM, Azithromycin did not show any effects 
on OCR.  However, at 50 μM, the effects of Azithromy-
cin clearly inhibited mitochondrial metabolism, 
especially effecting maximal respiration and spare res-
piratory capacity. In contrast, at 100 μM, Azithromycin 
actually stimulated maximal respiration and more than 
doubled spare respiratory capacity. This may represent a 
cellular compensatory response to Azithromycin treat-






























Figure  6.  Roxithromycin  shows  senolytic  activity  in  senescent MRC‐5  human  lung  fibroblasts.























































Validating the selectivity and potency of 
Azithromycin using BJ human fibroblasts 
 
To further validate the senolytic activity of 
Azithromycin, we also assessed its selective effects by 
employing normal, non-immortalized, BJ human skin 


















































more potent in BJ skin fibroblasts, showing significant 
“senolytic” activity at only 50 μM.  Remarkably, 
Azithromycin also increased the viability of normal BJ 
skin fibroblasts, by > 25 %. As such, Azithromycin 
shows comparable selectively and senolytic activity in 
human fibroblasts derived from two different anatomic 
sites (lung tissue and skin).  
Figure 7. Azithromycin strongly induces autophagy in MRC‐5 cells.  MRC‐5 cells were
treated  with  Azithromycin  at  50  µM  for  72  hours.  Then,  autophagy  was  monitored  by
























































Other drug candidates tested do not show any 
senolytic activity 
 
In parallel, we also tested a number of other drug 
candidates, using this senolytic assay system employing 



















































other drug candidates showed any specific senolytic 
activity, while sparing their normal fibroblast counter-
parts. These findings further highlight the specificity 
and selectivity of Azithromycin and Roxithromycin in 
the targeting of senescent cells. These results are 
included as Supplementary Table S1.  



































Independent validation of the high selectivity of 
Azithromycin for targeting senescent cells using the 
xCELLigence system 
  
Because senescent cells undergo the so-called 
senescence-associated secretory phenotype (SASP), 
which involves dramatic increases in the synthesis and 
secretion of proteins [1-7], we were concerned that our 
assay system – which measures protein – might be 
actually under-estimating the ability of Azithromycin to 
target senescent cells.  
  
To address this issue directly, we used another 
independent assay system (called xCELLigence) that 
does not depend on proteins, but instead uses electrical 
impedance to continuously measure cell proliferation, in 
a real-time fashion. Using this approach, we see that 
Azithromycin preferentially targets senescent cells, 
removing approximately 97% of them with great 
efficiency (Figure 11). This represents a near 25-fold 
reduction in senescent cells (p < 0.001). 
  
This real-time analysis also revealed that the population 
of normal control MRC-5 cells are also transiently 
affected by Azithromycin, but that they rapidly recover 































ing vehicle-alone control cell levels by > 30% (p < 
0.001). 
 
Therefore, this real-time assay system is superior to our 
static SRB assay, for more directly visualizing the 





New senolytic drugs: Azithromycin and 
Roxithromycin 
 
In this report, we used a “senolytic” screening approach 
to systematically identify clinically-approved drugs to 
target the senescence phenotype of human fibroblasts. 
For this purpose, we employed MCR-5 and BJ cells 
(two well-established non-immortalized human fibro-
blast cell lines), treated with BrdU - a DNA-damaging 
agent. Briefly, to induce cell cycle arrest and 
senescence, fibroblasts were exposed to BrdU (100 μM) 
to an 8-day period. After drug treatment for another 5 
days, cell attachment was assessed via the SRB assay 
system, using a plate-reader, allowing high throughput 
analysis.  As a result, using this screening approach, we 
discovered that two clinically-approved macrolide 
Figure  10.  Azithromycin  also  shows  senolytic  activity  in  senescent  BJ  human  skin
fibroblasts. BJ cells were pretreated with BrdU  for 8 days  (to  induce senescence), before  they were
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antibodies (namely, Azithromycin and Roxithromycin) 
preferentially exhibited “senolytic activity”. In contrast, 
the nearly identical drug, Erythromycin, did not show 
any toxicity towards senescent fibroblasts, directly 
demonstrating the high-specificity of the actions of 
Azithromycin and Roxithromycin. Metabolic analysis 
of the chemical effects of Azithromycin showed that it 
induced the onset of i) autophagy and ii) glycolysis.  
Moreover, Azithromycin increased mitochondrial 














































effect at a lower dose (50 μM), demonstrating clear bi-
phasic effects. We believe that these metabolic effects 
of Azithromycin could underpin its highly specific 
senolytic activity.  
 
Interestingly, Azithromycin is used clinically to 
chronically treat patients with cystic fibrosis [18], a 
genetic disease of the chloride-transporter, that 
generates a hyper-inflammatory state in lung tissue [19]. 
















































the xCELLigence  system. The  xCELLigence  system allows  for  the  real‐time,  label‐free, monitoring of  cell health and
behavior, via high frequency measurement of cell‐induced electrical impedance.  Panel (A) A representative cell tracing is
shown. Note that senescent cells (BrdU‐treated/MRC‐5 fibroblasts) were effectively killed; directly compare the red curve
(BrdU only)  versus  the green  curve  (BrdU plus Azithromycin).  For normal MRC‐5  fibroblasts,  compare  the black  curve
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the chloride transporter, followed by its degradation by 
proteases (most commonly the CFTR-ΔF508 mutation) 
[20]. In this context, Azithromycin extends patient 
lifespan by acting as an anti-inflammatory drug that 
prevents the onset of lung fibrosis by targeting and 
somehow eliminating “pro-inflammatory” lung fibro-
blasts [21, 22]. Therefore, the efficacy of Azithromycin 
in cystic fibrosis patients provides supporting clinical 
evidence for our current findings, as these lung 
fibroblasts are pro-inflammatory most likely because they 
are senescent.  Although this remains to be formally 
proven, it is well-known that the SASP generate a 
plethora of pro-inflammatory cytokines that rapidly 
spread the senescence phenotype to other neighboring 
cells and tissues, a phenomenon known as “inflamm-
aging”. Therefore, in the future, it may be useful to think 
about cystic fibrosis as a pro-aging disease, because of its 
genetic association with protein mis-folding, resulting in 
chronic inflammation and thereby driving shortened 
lifespan..  
 
In accordance with our current findings, Azithromycin 
treatment is also protective against radiation-induced 
lung damage in mice. Radiation is considered as a pro-
aging stimulus, as it accelerates DNA damage, ROS 
production and oxidative stress, as well as inflammation 
and fibrosis. In this model system, Azithromycin 
treatment morphologically inhibited the onset of lung 
inflammation and fibrosis, as well as quantitatively 
prevented the accumulation of markers of i) oxidative 
stress (MDA; malondialdehyde), ii) inflammation (IL1-
beta, IL-6, TNA-alpha) and iii) fibrosis (TGF-beta-1, 
Alpha-SMA, Collagen I) [23]. In the context of TGF-
beta-1, Collagen I and Alpha-SMA, it has also been 
proposed that Azithromycin prevents the onset of the 
myo-fibroblast phenotype [24]. However, in light of our 
current data, we suggest instead that myo-fibroblasts are 
actually senescent cells, which are rapidly and 
effectively eliminated by Azithromycin.  
 
In addition, Roxithromycin has been shown to effectively 
promote hair re-growth [25-27], possibly by stimulating 
the production of normal hair follicle stem cells. 
Mechanistically, this hair re-growth phenomenon could 
be due to the highly efficient removal of neighboring 
senescent skin fibroblasts. Moreover, Roxithromycin has 
also been reported to have stronger anti-inflammatory 
effects, than both Azithromycin and Erythromycin [28].  
 
Does autophagy confer “senolytic” activity?  
 
It is now well-established that autophagic cells have an 
increased likelihood of becoming senescent. This is 
called the autophagy-senescence transition (AST). More 
specifically, during autophagy, cells accumulate auto-
phagic organelles (lysosomes and auto-phagosomes). 
These structures normally sequester dangerous proteases, 
including the cathepsins (B, S and L).  However, during 
an acute stress, lysosomes in autophagic cells can 
become “leaky”, resulting in the release of the cathepsins 
into the cytosol, secondrary to lysosome rupture or 
defects in the lysosomal membrane [29].  Once in the 
cytosol, the cathepsins can proteolytically cleave the 
sirtuins, such as SIRT1, driving the senescence pheno-
type [29]. Interestingly, we show here that Azithromycin, 
a weak autophagy inducer, preferentially targets 
senescent cells. Thus, we speculate that the induction of 
autophagy in senescent cells can drive cell death (Figure 
12). Undoubtedly, further experimentation will be 

































In summary, we conclude that it is possible to identify 
pre-existing clinically-approved antibiotics with 
senolytic activity, for drug repurposing as anti-aging 
drugs that can be used to target senescent fibroblasts.  
The specific examples we provide are Azithromycin 
and Roxithromycin, two well-known macrolide anti-
biotics.  
Figure  12.  Potential  role  of  autophagy  in  conferring
“senolytic”  activity.    Autophagic  cells  have  an  increased  ten‐
dency  to  become  senescent.    Mechanistically,  autophagic  cells
accumulate  large  numbers  of  lysosomes  and  auto‐phagosomes.
These  organelles  contain  high  levels  of  proteases,  such  as
cathepsins  (B,  S  and  L).    Interestingly,  it  has  been  previously
demonstrated  that  lysosomes  in  authophagic  cells  can  become
“leaky”  due  to  an  acute  stress,  ultimately  resulting  in  stress‐
induced senescence  (SIS). As a consequence, cathepsins  leak  into
the cytoplasm where they can then cleave sirtuin family members
(e.g., SIRT1), paving  the way  for  the onset of  senescence.   Here,
we  show  that  a  weak  autophagy  inducer,  Azithromycin  (AZ),
selectively  targets  senescent  cells. We  speculate  that  the weak
induction of autophagy in senescent cells can result in cell death.  
www.aging‐us.com  11  AGING 




MRC-5 (ATCC® CCL-171) human lung fibroblast cells 
and BJ (ATCC® CRL2522) human skin fibroblasts were 
purchased from the ATCC (American Type Culture 
Collection). Gibco-brand cell culture media (MEM) was 
purchased from Life Technologies. Bromodeoxyuridine, 
Azithromycin, Roxithromycin and Erythromycin were 
purchased from Sigma-Aldrich. Azithromycin (from 
Pfizer) is FDA-approved. Roxithromycin (from GSK 
and Sandoz) is not available in the United States, but is 





MRC-5 or BJ cells were plated into 24-well plates. Next 
day, half of the plate was treated with 100 µM of 
Bromodeoxyuridine (BrdU) while control wells were 
treated with vehicle only (DMSO) and incubated for 8 
days at 37°C in a 5% CO2 humidified atmosphere. 
After 8 days of BrdU treatment cells were treated with 
various compounds (Azithromycin, Roxithromycin or  
Erythromycin) for another 3-5 days. BrdU or vehicle 
treatments were continued during the drug treatments as 
well.  
 
Sulphorhodamine B assay 
 
After the incubation of the plates cell viability was 
measured by Sulphorhodamine B assay (SRB). The 
assay is based on the measurement of cellular protein 
contents. Cells were fixed with 10% Trichloroacetic 
acid (TCA) for 1 hour at 4oC, and were dried overnight 
at room temperature. Then, plates were incubated with 
SRB for 30 min, washed twice with 1% acetic acid and 
air dried for at least 1h. Finally, the protein-bound dye 
was dissolved in a 10 mM Tris, pH 8.8, solution and 
read using a plate reader at 540-nm. 
 
Autophagy and Cell cycle analysis 
 
Autophagy (using Muse™Autophagy LC3-antibody 
based Kit, Merck Millipore) and cell cycle (Muse® Cell 
Cycle Kit, Merck Millipore) experiments were 




Beta-Galactosidase staining of BrdU-treated MRC-5 
cells was performed by Senescence β-Galactosidase 
Staining Kit (#9860, Cell Signaling Technology Inc.) 
and was done according to manufacturer`s protocol. 
Seahorse XFe96 metabolic flux analysis 
 
Extracellular acidification rates (ECAR) and real-time 
oxygen consumption rates (OCR) for MCF7 cells were 
determined using the Seahorse Extracellular Flux 
(XF96) analyzer (Seahorse Bioscience, MA, USA) [30]. 
MRC-5 cells were maintained in MEM supplemented 
with 10% FBS (foetal bovine serum), 2 mM 
GlutaMAX, and 1% Pen- Strep. 40,000 cells per well 
were seeded into XF96-well cell culture plates, and 
incubated overnight at 37°C in a 5% CO2 humidified 
atmosphere. Next day, cells were treated with 
Azithromycin for 72 hours. Before the experiment, plate 
was washed with pre-warmed XF assay media (for OCR 
measurement, XF assay media was supplemented with 
10mM glucose, 1mM Pyruvate and adjusted at pH 7.4). 
Cells were then maintained in 175 μL/well of XF assay 
media at 37°C, in a non-CO2 incubator for 1h. During 
incubation, 25 μL of of 80mM glucose, 9μM 
Oligomycin, 1M 2-deoxyglucose (for ECAR measure-
ment) and 25 μL of 10μM Oligomycin, 9 μM FCCP, 10 
μM Rotenone, 10 μM Antimycin A (for OCR 
measurement) in XF assay media was loaded into the 
injection ports of the XFe-96 sensor cartridge. During 
the experiment, the instrument injected these inhibitors 
into the wells at a given time point, while ECAR/OCR 
was measured continuously. ECAR and OCR mea-
surements were normalized by protein content 
(Sulphorhodamine B assay). Data sets were analyzed by 
XFe-96 software, using one-way ANOVA and 
Student’s t-test calculations. All experiments were 
performed in triplicate. 
 
xCELLigence RTCA System (ACEA Biosciences Inc.) 
 
Briefly, MRC-5 lung fibroblasts (vehicle alone and/or 
treated with 100 μM BrdU) were seeded in each well 
and employed to assess the efficacy of Azithromycin, 
using RTCA (real-time cell analysis), via the 
measurement of cell-induced electrical impedance. This 
approach allows the quantification of the onset and 
kinetics of the cellular response. Experiments were 
repeated several times independently, using 




Statistical significance was determined using the 
Student’s t-test; values of less than 0.05 were considered 
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